Forget Johnson & Johnson: This Name Has WAY More Upside Than JNJ Stock

Johnson & Johnson to seek approval for 10 potential blockbusters in next 4 years

|Chart | Calendar   | TRADE NOW |Johnson & Johnson

Johnson & Johnson to seek approval for 10 potential blockbusters in next 4 years

BUZ INVESTORS  Johnson & Johnson to seek approval Johnson & Johnson (JNJ), -0.41% said Wednesday that it, along with its Janssen Pharmaceutical Companies, plans to file for regulatory approval 10 new potential blockbuster drugs between this year and 2021. The company said it also plans more than 50 line extensions of existing and new medicines through 2021. “With a growing core business of differentiated medicines and a strong line-up of innovative products expected to launch or file over the next five years, we are leading the industry in advancing the health of patients around the world,” said J&J Chief Executive Alex Gorsky.



 Johnson & Johnson to seek approval

In this morning’s Pharmaceutical Business Review, Johnson & Johnson’s (JNJ)-0.6%) Worldwide Chairman, Pharmaceuticals, Joaquin Duato said 75% of the company’s growth in drug sales were driven by volume growth as opposed to price hikes over the period 2012 – 2016.

He added that the company expects a re-acceleration of growth in its pharma business this year which should continue through 2021.

Source: The Fly

Business Description

Industry: Drug Manufacturers » Drug Manufacturers – Major    NAICS: 325412    SIC: 2834
Compare: OTCPK:(RHHBY), NYSE:(PFE), OTCPK:(NVSEF), NYSE:(MRK), NYSE:(SNY), OTCPK:(GLAXF), NYSE:(ABBV), OTCPK:(BAYZF), NYSE:(BMY), NYSE:(LLY), NYSE:(AZN), OTCPK:(SZUKF), OTCPK:(ALPMY), OTCPK:(OTSKY), OTCPK:(CHGCY), OTCPK:(DSNKY), OTCPK:(OPHLY), OTCPK:(CHPTY), OTCPK:(SNPHY), OTCPK:(PTKFY) » details
Traded in other countries: JNJ.Argentina, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location: USA

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world’s largest and most diverse healthcare company. Three divisions make up the company: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. About half of total revenue is generated within the United States.
Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Featured Video Play Icon

Nemaska Lithium CEO on the “very strong message” behind the Johnson Matthey deal

Nemaska Lithium CEO on the “very strong message” behind the Johnson Matthey deal

THE BUZ ON LITHIUM

  • Buz Investors Nemaska Lithium In a special InvestorIntel interview, Publisher Tracy Weslosky speaks with Guy Bourassa, President, CEO and Director for Nemaska Lithium Inc. (TSXV:NMX | OTCQX:NMKEF)
  • about the 166% increase in stock in 2015 and the Johnson Matthey MOU. Specifically, Guy discusses the competitive advantage of securing the Johnson Matthey MOU with “an end-user that is willing to put money upfront to make sure that it will create a new production supply…”
  • and goes onto add: “that’s a very, very strong message on how tight the market is and how the outlook also looks.”

Nemaska Lithium

 Buz Investors Nemaska Lithium In a special InvestorIntel interview, Publisher Tracy Weslosky speaks with Guy Bourassa, President, CEO and Director for Nemaska Lithium Inc. (TSXV:NMX | OTCQX:NMKEF) about the 166% increase in stock in 2015 and the Johnson Matthey MOU. Specifically, Guy discusses the

Nemaska Lithium Tracy Weslosky: Guy, your stock was up 166% in 2015. Can you tell us what you can attribute this to?

Guy Bourassa: Well, we delivered what we said we were going to do. The market was quite flat for most of the year, but in expectation of us getting all the permits required to start building an operation of the Whabouchi Mine. So, if you look at the chart it exactly reflects the decisions that were rendered, federal government at the end of July stock started to rise on this. Early September, provincial government gave us the certificate of authorization, another spike. It maintained very good liquidity because we have strong believers in our stock, long-term shareholders, and they were all expecting a long due process to be approved.

More Buz on Lithium Buz Traders Share

Nemaska Lithium

Tracy Weslosky: Of course let’s not forget your MOU signing with Johnson Matthey. I think our audience really needs to appreciate as much as we do how substantial that agreement signing actually was.

Guy Bourassa: It is one of a kind and obviously it reflected very strongly on the stock. The MOU we signed with Johnson Matthey has never been seen in the lithium sector. It has never been seen of an end-user, actual credible large end-user of lithium compound that is willing to pay upfront $12 million dollars on goods and services coming from a plant that is not even built. It’s not some sort of a potential letter of intent. It’s a real hard money put upfront for goods and services.

Tracy Weslosky: Of course you managed to sign a deal with real cash. Can you talk to us a little bit about the capital component of this deal please?

Guy Bourassa: Yes. It’s a $12 million dollar Canadian upfront payment for goods, mainly lithium compounds that will come out of the Phase 1 plant that we’re starting to build this quarter in Chibougamau. It’s very interesting because it also shows how tight the market is presently. So for an end-user that is willing to put money upfront to make sure that it will create a new production supply — that’s a very, very strong message on how tight the market is and how the outlook looks also.

Tracy Weslosky: Okay, interesting. Also, Christopher Ecclestone, one of our global analysts at InvestorIntel, said you’re going to be the first “girl to the dance”, I believe is his quote and one of the few that will make it — one of the few in a handful that will make it to production…to access the complete interview, click here

 

Commodities ( Gold ) ( Silver ) ( Lithium )




Forget Johnson & Johnson: This Name Has WAY More Upside Than JNJ Stock

Forget Johnson & Johnson: This Name Has WAY More Upside Than JNJ Stock

Forget Johnson & Johnson: This Name Has WAY More Upside Than JNJ Stock

  • Buz Trader Alert  More Upside Than JNJ  Johnson & Johnson (NYSE:JNJ) has always been a trusted name for anyone who has ever sought out any type of medical or personal care product, including shampoo,  bandages, and over-the-counter medications.
  • Johnson & Johnson operates with three segments; “Consumer Healthcare,” Pharmaceuticals,” and “Medical Devices.” They have amassed a huge range of products that cater to many medical and non-medical needs. JNJ stock has done well for investors in 2016, up 18% year-to-date.
  • As a parent, I am guilty of shopping for brand names I am familiar with because, when it come to my family, I want the best products, from companies that are also accountable for those products. Products that contain JNJ on their packaging leave me feeling safe and secure with my purchase.

More Upside Than JNJ  Competition Has a Leg Up

Forget Johnson & Johnson: This Name Has WAY More Upside Than JNJ Stock

More Upside Than JNJ A name that is not as distinguished as Johnson & Johnson, and probably not as well-known by parents, is Natus Medical Inc (NASDAQ:BABY). The stock ticker alone should give you some sense of what segment of the population around which this company bases its products and services.  Natus Medical is the leading manufacturer and service provider for medical devices that cater to newborn care. I actually prefer companies that focus on one niche aspect, as all of their attention is focused on one goal. In this space, I believe that Natus medical has a leg up on Johnson & Johnson.

BABY stock generated a golden cross in August 2016. A golden cross is a bullish signal that is produced when a faster 50-day moving average (highlighted in blue) crosses above a slower 200-day moving average (highlighted in red). Traders use this signal to confirm that a bull market is on the horizon. I find it always wise to trade in the direction of this signal.

Other Stories Buz Investors are following

The golden cross comes on the heels of a death cross that was generated in February 2016. A death cross is the exact opposite of a golden cross and suggests that a bear market is on the horizon. This signal was effective as BABY made new lows following this signal.

The price of BABY stock is confirmed by this indicator, as the rally off the April lows is confirmed by OBV. This indicator is making higher highs that match the price action in the share price. Money is flowing into BABY stock and supports the premise of higher prices.

images

screenarticleInstaForex analytical reviews will make you fully aware of market trends! Being an InstaForex client, you are provided with a large number of free oie_Rp2d7HVSccxfservices for efficient trading.

Johnson & Johnson: 1 Dividend inventory to own all the time

Johnson & Johnson: 1 Dividend inventory to own all the time

Johnson & Johnson: 1 Dividend inventory to own all the time

Investors Buz   –    Global Markets Roundup

Johnson & Johnson: 1 Dividend inventory to own all the time

Johnson and Johnson: A strong Dividend pick

Healthcare and customer items companies may not sound as interesting as internet ones, however in this extremely-low hobby fee surroundings, it can be profitable to check Johnson & Johnson (NYSE:JNJ) inventory.
initially, permit’s get one element out of the way: while you are watching Johnson & Johnson stock, you’re not going after triple-digit gains. What you really need from this century-antique business enterprise is dividends.

in terms of dividends, JNJ inventory is an instance of a strong select. The business enterprise has been increasing its quarterly payout for 54 consecutive years. The state-of-the-art dividend hike become introduced this April, whilst Johnson & Johnson raised its quarterly dividend charge through 6.7% to $0.80 consistent with proportion. On an annualized basis, JNJ stock has a dividend yield of two.56%. (supply: “Johnson & Johnson announces Dividend increase of 6.7%,” Johnson & Johnson, April 28, 2016.)

in terms of dividends, JNJ stock is an instance of a solid pick. The agency has been growing its quarterly payout for 54 consecutive years. The modern day dividend hike turned into introduced this April, while Johnson & Johnson raised its quarterly dividend rate via 6.7% to $zero.eighty in step with proportion. On an annualized basis, JNJ inventory has a dividend yield of two.56%. (supply: “Johnson & Johnson announces Dividend boom of 6.7%,” Johnson & Johnson, April 28, 2016.)
300x250 new sheriff en 08.10.2014

JNJ inventory’s varied international commercial enterprise

if you are an profits investor, you probably recognise that putting all your eggs in one basket is a terrible concept. the best information is that Johnson & Johnson runs a quite different commercial enterprise. Its tens of billions of greenbacks of annual income come from three segments: purchaser, pharmaceutical, and scientific gadgets.
As nicely, the employer has operations around the world. JNJ’s products are sold through 250 operating businesses in 60 international locations. furthermore, approximately forty nine% of its income come from out of doors of the U.S. (supply: “Investor fact Sheet,” Johnson & Johnson, last accessed July 24, 2016.)
Johnson & Johnson stock Is Recession-evidence
With the arena economic system being what it is these days, what if increase slows down or any other recession hits? properly, in that case, Johnson & Johnson’s purchaser phase is probably negatively affected, however its

pharmaceutical segment is recession-evidence.

you notice, aside from making baby care merchandise and “Band-Aids,” the company markets extra than a hundred distinctive capsules. It has forty six pills with greater than $50.0 million in annual income, 34 tablets with extra than $100 million, and eleven tablets with extra than $1.0 billion. (source: Ibid.)
moreover, no matter having a large presence, the segment continues to be growing at a decent tempo. within the second zone of 2016, Johnson & Johnson’s global pharmaceutical income rose eight.nine% yr-over-12 months to $8.7 billion. sales in the U.S. improved by means of thirteen.2%. global sales climbed a stable 3.1% despite a 1.8% terrible impact from exchange rate fluctuations. (source: “Johnson & Johnson reports 2016 2nd-area effects,” Johnson & Johnson, July 19, 2016.)
mainly, sturdy boom in new products which include “IMBRUVICA,” “Xarelto,” and “Darzalex” helped power increase in JNJ’s pharmaceutical segment. at the equal time, its middle products keep to perform properly.
Pharmaceutical and healthcare organizations are conventional examples of corporations with extraordinarily inelastic demand for his or her merchandise. that is, whilst financial increase slows down or even whilst a recession hits, their organizations are much less affected than maximum different groups because they sell products humans want, no matter disposable income.
With a large pharmaceutical section, JNJ inventory may want to provide recession-proof income for dividend investors.

JNJ inventory’s affordable Valuation

at the cease of the day, the rate must be proper, although. As Warren Buffett’s proper-hand guy Charlie Munger places it, “no matter how exceptional a business is, it’s no longer well worth an infinite rate.” happily, notwithstanding the fact that the U.S. stock marketplace currently surpassed its all-time highs, valuations seem to be pretty affordable for Johnson & Johnson.
on the midpoint of the enterprise’s full-yr 2016 steering, the employer generated $6.sixty eight in earnings according to proportion. meaning that at these days’s charge, JNJ inventory is trading at 18.7 instances its profits—lower than a lot of its competitors in the healthcare sector. This gives JNJ stock traders a margin of protection.
the lowest line: in case you are looking for a organisation that gives secure and growing dividends, Johnson & Johnson inventory ought to be close to the top of your watch list.